(A) Representative flow cytometric analysis of CD71 and Ter119 staining in WT and Samd14-Enh-/- spleen following PHZ treatment. (B) Quantitation of the percentage (top) and cell number (bottom) per spleen of CD71+Ter119- and Ter119+ cells in WT and Samd14-Enh-/- mice. (C) Relative Samd14 mRNA levels in FACS-purified cells from WT spleen and Samd14-Enh-/- spleen (n = 3). (D) Relative Gata2 mRNA levels in FACS-purified cells from WT spleen and Samd14-Enh-/- spleen (n = 3). (E) Relative Gata1 mRNA levels in FACS-purified cells from WT spleen and Samd14-Enh-/- spleen (n = 3). (F) Relative Kit mRNA levels in FACS-purified cells from WT spleen and Samd14-Enh-/- spleen (n = 3). (G) Relative Scl/TAL1 mRNA levels in FACS-purified cells from WT spleen and Samd14-Enh-/- spleen. (H) Flow cytometric analysis of percentages of c-Kit+CD71+ cells within the Ter119- population of PHZ-treated spleen (n = 4). (I) Relative Samd14, Gata2, and Scl/TAL1 mRNA levels in FACS-purified cells from WT spleen and Samd14-Enh-/- spleen. (J) Quantitation of percentages of live (DRAQ7-AnnexinV-), early apoptotic (DRAQ7-AnnexinV+), late apoptotic (DRAQ7+AnnexinV+), and dead (DRAQ7+AnnexinV-) cells in CD71+c-Kit+Ter119- cells in PHZ-treated WT and Samd14-Enh-/- spleen (n = 4). Statistical significance represented by mean +/- SEM.; *p<0.05, ***p<0.001.